Phase 2 Study of Denifanstat Looks to Add First-in-Class Agent to HER2+Breast Cancer Treatment Armamentarium
Phase 2 trial investigators hope denifanstat can be a key component in restoring sensitivity to HER2- positive metastatic breast cancer treatments.
Source: onclive.com